Kangji Medical takeover scheme document delayed; J.P. Morgan discloses share dealings

J.P. Morgan Securities PLC, an associate connected with the offeror, disclosed its dealings in Kangji Medical Holdings Limited shares on September 1, 2025. The firm sold 18,500 shares for $159,305.48. These transactions, described as "other types of securities" and "hedging of Delta 1 products," were made for J.P. Morgan Securities PLC's own account.

Concurrently, Knight Bidco Limited and Kangji Medical Holdings Limited announced a delay in despatching the scheme document related to the privatization proposal. Originally due by September 2, 2025, an extension was granted until October 31, 2025. This delay is attributed to the need to fulfill pre-conditions, finalize the document, and obtain Grand Court directions, considering the court's vacation.

The privatization proposal, by way of a scheme of arrangement, remains subject to pre-conditions. The scheme document will provide further details, an expected timetable, and recommendations from the independent board committee and financial adviser. Shareholders and potential investors are cautioned to exercise prudence, as the proposal's implementation is not guaranteed.